Brain Protein PSD-95 Could Target Cognitive Decline
University of Illinois researchers identified a protein that may help treat cognitive decline in certain neurological disorders.
Updated on Oct. 28, 2026 in Alzheimer’s
Live Poll
Do you believe current genetic research investment is effectively improving treatment options for rare neurological diseases?
University of Illinois researchers have identified the protein PSD-95 as a potential therapeutic target for neurological conditions linked to MEF2C gene deletions. This preclinical finding suggests a pathway for addressing cognitive decline and seizures in disorders such as Alzheimer’s disease.
Why it matters
MEF2C haploinsufficiency disrupts normal brain function by failing to regulate PSD-95, leading to its toxic accumulation. This study provides a foundational understanding of how restoring this protein balance might mitigate neurological symptoms.
In a preclinical study published in the Proceedings of the National Academy of Sciences, researchers demonstrated that PSD-95 levels are elevated in mice with MEF2C haploinsufficiency. Inhibiting this protein through genetic and pharmacological methods restored cognitive performance in the animal subjects.
The players
University of Illinois
A public research university where investigators conducted the study on MEF2C and PSD-95.
National Institutes of Health
The primary federal agency responsible for biomedical research that provided funding for this study.
The details
MEF2C normally acts as a regulator that ensures PSD-95 is degraded at appropriate rates within the brain. When MEF2C levels are insufficient, PSD-95 accumulates in the synapses, which impairs neural signaling and leads to cognitive issues and seizures. By reducing the presence of PSD-95 or inhibiting its interaction with receptors, researchers were able to normalize these signaling pathways in mice.
Timeline
October 27, 2026: The research findings were published in the Proceedings of the National Academy of Sciences.
Health Landscape
This research aligns with ongoing efforts to map molecular drivers of neurodegenerative and neurodevelopmental conditions. It expands the understanding of how synaptic protein regulation sits at the intersection of autism, epilepsy, and Alzheimer’s disease research.
This study remains in the preclinical phase and does not currently change existing treatment protocols for Alzheimer’s or related disorders. Residents with concerns about cognitive decline should prioritize conversations with a physician regarding established diagnostic and management options.
The takeaway
This discovery highlights the importance of synaptic protein balance in maintaining cognitive function. While promising, this research is limited to animal models, and interested readers should follow future updates on therapeutic developments for these signaling pathways.
Further reading
For more on the current understanding of memory and cognitive health, visit Alzheimer’s.
Source note: This article includes information reported by Herald-Review.
Live Poll
Do you believe current genetic research investment is effectively improving treatment options for rare neurological diseases?
